2014-03-31 – Page 8 – China Stock Advice

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: (Original Filing)

[TABLE OF CONTENTS Page PART I 3 Item 1. Business 3 Item 1A. Risk Factors 10 Item 1B. Unresolved Staff Comments 20 Item 2. Properties 20 Item 3. Legal Proceedings 22 Item 4. Mine Safety Disclosures 23 PART II 23 Item 5. 23 Item 7. Management’s Discussion and Analysis of Financial Conditions and Results of Operations] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192657) and Registration Statement on Form S-8 (No. 333-181010) of our report dated March 31, 2014, relating to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and its subsidiaries (collectively the “Company”), which appears in this Annual] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Bing Mei Chief Financial Officer]

By info| 2016-03-27T16:14:02+00:00 March 31st, 2014|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-K, 2014-03-31, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CJJD [CHINA JO-JO DRUGSTORES] 8-K: FORM 8-K CURRENT REPORT Date of report (Date

[FORM 8-K CURRENT REPORT Date of report (Date of earliest event reported): March 31, 2014 (March 28, 2014) CHINA JO-JO DRUGSTORES, INC. Nevada 001-34711 98-0557852 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) 1st Floor, Yuzheng Plaza No.76, Yuhuangshan Road Hangzhou, Zhejiang Province People’s Republic of China (Zip Code) +86 (571) 88077078 N/A (Former name]

By info| 2016-04-01T02:47:53+00:00 March 31st, 2014|Categories: Chinese Stocks, CJJD, Webplus ver|Tags: 0001413263, 2014-03-31, 2833, 8-K, CJJD, MEDICINAL CHEMICALS and BOTANICAL PRODUCTS|0 Comments

WUBA [58.com] 6-K: 58.com Announces Pricing of Follow-on Public Offering of

[58.com Announces Pricing of Follow-on Public Offering of American Depositary Shares BEIJING, CHINA, March 28, 2014 -- 58.com Inc. (NYSE: WUBA) (the “Company”) today announced that the previously announced registered follow-on public offering of American depositary shares (“ADSs”) by the Company and certain selling shareholders was priced at US$38.00 per ADS. The Company will issue and sell 2,000,000 ADSs and] []

By info| 2016-03-15T08:05:00+00:00 March 31st, 2014|Categories: Chinese Stocks, Webplus ver, WUBA|Tags: 0001525494, 2014-03-31, 6-K, 7370, SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC., WUBA|0 Comments

MONT [MONTAGE TECHNOLOGY] 8-K: (Original Filing)

[Montage Technology Announces Preliminary First Quarter Revenue Results Exceeding Guidance SHANGHAI, China March 31, 2014 The increased revenue expectations reflect higher sales of Montages memory interface solutions due to growing demand for LRDIMMs. As a result, memory interface revenue is expected to increase more than 60 percent sequentially. Gross margin for the first quarter 2014 is expected to be] [Montage Technology Announces Filing of Form 12b-25 Notification of Late Filing for 2013 10-K SHANGHAI, China, March 31, 2014 Form 12b-25 Notification of Late Filing for 2013 10-K. In its 12b-25 Notification of Late Filing, the Company indicated that its Form 10-K cannot be finalized until the completion of the audit committees review of allegations contained in reports issued by] [Item 7.01 Regulation FD Disclosure Item 8.01 Other Events 99.1 Press Release dated March 31, 2014 announcing revised earnings guidance.]

By info| 2016-03-20T01:52:43+00:00 March 31st, 2014|Categories: Chinese Stocks, MONT, SEC Original|Tags: 0001375514, 2014-03-31, 3674, 8-K, MONT, SEMICONDUCTORS and RELATED DEVICES|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: TABLE OF CONTENTS Page PART I 3 Item

[TABLE OF CONTENTS Page PART I 3 Item 1. Business 3 Item 1A. Risk Factors 10 Item 1B. Unresolved Staff Comments 20 Item 2. Properties 20 Item 3. Legal Proceedings 22 Item 4. Mine Safety Disclosures 23 PART II 23 Item 5. 23 Item 7. Management’s Discussion and Analysis of Financial Conditions and Results of Operations] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192657) and Registration Statement on Form S-8 (No. 333-181010) of our report dated March 31, 2014, relating to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and its subsidiaries (collectively the “Company”), which appears in this Annual] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. March 31, 2014 Bing Mei Chief Financial Officer]

By info| 2016-03-27T16:15:26+00:00 March 31st, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-K, 2014-03-31, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

TAOM [Taomee] 6-K: (Original Filing)

[Taomee Announces Share Repurchase Plan The share repurchase plan will be funded by the Companys free cash flow as well as existing working capital. As of December 31, 2013, the Company had cash and cash equivalents of approximately US$114.3 million. As of March 27, 2014, the Company had 757,684,760 ordinary shares issued and outstanding. About Taomee Holdings Limited Taomee Holdings] [TAOMEE HOLDINGS LIMITED 16/F, Building No. A-2, No. 1528 Gumei Road, Xuhui District Shanghai 200233, Peoples Republic of China (86-21) 6128-0056 Form 20-F x Form 40-F o o o Yes o No x 82- N/A TAOMEE HOLDINGS LIMITED]

By info| 2016-04-01T10:25:39+00:00 March 31st, 2014|Categories: Chinese Stocks, SEC Original, TAOM|Tags: 0001507051, 2014-03-31, 6-K, 7389, SERVICES-BUSINESS SERVICES, NEC, TAOM|0 Comments